



## Apogee Therapeutics to Participate in Upcoming November Investor Conferences

October 30, 2023

SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- [Apogee Therapeutics, Inc.](#) (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will present at the following upcoming investor conferences:

### **Guggenheim Securities 5<sup>th</sup> Annual Inflammation, Neurology & Immunology Conference**

Date: Monday, November 6, 2023

Time: 2:30 p.m. ET

### **Stifel 2023 Healthcare Conference**

Date: Tuesday, November 14, 2023

Time: 10:20 a.m. ET

### **Jefferies London Healthcare Conference**

Date: Wednesday, November 15, 2023

Time: 11:30 a.m. ET

### **Evercore ISI 6<sup>th</sup> Annual HealthCONx Conference**

Date: Tuesday, November 28, 2023

Time: 11:15 a.m. ET

A live and archived webcast of the fireside chats and presentations will be available via the [News & Events](#) page in the Investors section of the Apogee Therapeutics website.

### **About Apogee Therapeutics**

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company's two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit [www.apogeetherapeutics.com](http://www.apogeetherapeutics.com).

### **Investor Contacts:**

Noel Kurdi  
VP of Investor Relations  
Apogee Therapeutics  
[noel.kurdi@apogeetherapeutics.com](mailto:noel.kurdi@apogeetherapeutics.com)

Bill Slattery  
THRUST Strategic Communications  
[bill@thrustsc.com](mailto:bill@thrustsc.com)

### **Media Contact:**

Dan Budwick 1AB Media  
[dan@1abmedia.com](mailto:dan@1abmedia.com)



Source: Apogee Therapeutics, LLC